TCIM
AXDX

TIAA CREF Investment Management’s Accelerate Diagnostics AXDX Stock Holding History

TIAA CREF Investment Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.1M Sell
5,235
-44
-0.8% -$8.25K ﹤0.01% 2276
2018
Q4 		$607K Hold
5,279
– – ﹤0.01% 2489
2018
Q3 		$1.21M Sell
5,279
-660
-11% -$146K ﹤0.01% 2357
2018
Q2 		$1.32M Sell
5,939
-406
-6% -$90.8K ﹤0.01% 2384
2018
Q1 		$1.45M Buy
6,345
+243
+4% +$63.8K ﹤0.01% 2263
2017
Q4 		$1.6M Sell
6,102
-655
-10% -$154K ﹤0.01% 2248
2017
Q3 		$1.52M Sell
6,757
-225
-3% -$55.3K ﹤0.01% 2314
2017
Q2 		$1.91M Buy
6,982
+779
+13% +$211K ﹤0.01% 2211
2017
Q1 		$1.5M Sell
6,203
-433
-7% -$98.9K ﹤0.01% 2306
2016
Q4 		$1.38M Sell
6,636
-406
-6% -$96.4K ﹤0.01% 2379
2016
Q3 		$1.92M Buy
7,042
+117
+2% +$25.9K ﹤0.01% 2198
2016
Q2 		$997K Sell
6,925
-793
-10% -$106K ﹤0.01% 2508
2016
Q1 		$1.11M Buy
7,718
+537
+7% +$75.8K ﹤0.01% 2418
2015
Q4 		$1.54M Hold
7,181
– – ﹤0.01% 2322
2015
Q3 		$1.16M Sell
7,181
-1,006
-12% -$218K ﹤0.01% 2479
2015
Q2 		$2.11M Buy
8,187
+282
+4% +$67.3K ﹤0.01% 2269
2015
Q1 		$1.78M Sell
7,905
-219
-3% -$45.8K ﹤0.01% 2289
2014
Q4 		$1.56M Sell
8,124
-181
-2% -$38.7K ﹤0.01% 2400
2014
Q3 		$1.78M Sell
8,305
-206
-2% -$40.1K ﹤0.01% 2298
2014
Q2 		$2.21M Buy
8,511
+3,795
+80% +$828K ﹤0.01% 2241
2014
Q1 		$1.03M Sell
4,716
-205
-4% -$30.4K ﹤0.01% 2634
2013
Q4 		$600K Buy
4,921
+296
+6% +$39.6K ﹤0.01% 2909
2013
Q3 		$620K Buy
4,625
+613
+15% +$54.7K ﹤0.01% 2877
2013
Q2 		$326K Buy
+4,012
New +$298K ﹤0.01% 3016

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

TIAA CREF Investment Management's AXDX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Accelerate Diagnostics (AXDX) stake by 0.83% in Q1 2019, selling an estimated $8.25K and leaving 5,235 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

TIAA CREF Investment Management first reported a position in AXDX in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.21M in Q2 2014. 114 funds tracked by Wall St. Rank hold AXDX as of Q1 2019.

  • TIAA CREF Investment Management held 5,235 shares of Accelerate Diagnostics worth $1.1M as of Q1 2019.
  • TIAA CREF Investment Management sold 44 Accelerate Diagnostics shares in Q1 2019, an estimated $8.25K.
  • Accelerate Diagnostics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2276 holding.
  • TIAA CREF Investment Management first reported a position in Accelerate Diagnostics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Accelerate Diagnostics position peaked at $2.21M in Q2 2014.
  • 114 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.